influenza
b
genom
rna
segment
encod
structur
nonstructur
protein
virus
infect
cell
genet
reassort
occur
gener
new
strain
subtyp
reassort
human
avian
viru
strain
gave
rise
influenza
pandem
degre
swine
infect
human
avian
virus
thu
serv
mix
vessel
facilit
emerg
new
subtyp
may
may
readili
transmit
highli
pathogen
avian
virus
transmit
directli
bird
human
result
high
mortal
fortun
date
low
transmiss
addit
mutat
occur
routin
replic
lead
antigen
chang
influenza
type
b
uniqu
abil
influenza
virus
chang
genet
antigen
makeup
lead
annual
epidem
ill
hospit
excess
mortal
well
continu
threat
new
pandem
potenti
higher
morbid
mortal
diagnost
laboratori
challeng
provid
assay
detect
circul
strain
year
year
although
test
typic
target
conserv
np
gene
protein
test
perform
valid
annual
especi
new
virus
emerg
influenza
transmit
primarili
droplet
spread
sneez
cough
also
contact
infect
surfac
via
smallparticl
aerosol
enter
respiratori
tract
influenza
virion
attach
via
ha
envelop
protein
sialic
acid
receptor
ciliat
columnar
epitheli
cell
cleavag
ha
cellular
proteas
viru
endocytos
replic
ensu
essenti
step
viral
releas
infect
remov
sialic
acid
residu
envelop
new
virion
viral
neuraminidas
incub
day
viru
shed
symptom
appear
viral
shed
last
day
begin
decreas
within
day
symptom
onset
uncompl
influenza
character
abrupt
onset
malais
headach
myalgia
fever
follow
sore
throat
nonproduct
cough
children
may
also
develop
otiti
media
nausea
vomit
influenza
typic
caus
tracheobronch
resolv
within
week
cough
malais
persist
week
longer
complic
includ
febril
seizur
young
children
sinus
viral
pneumonia
secondari
bacteri
pneumonia
myocard
pericard
encephalopathi
older
adult
may
present
fever
rather
decompens
underli
cardiac
pulmonari
condit
main
focu
influenza
manag
prevent
vaccin
annual
vaccin
recommend
person
older
month
treatment
indic
treatment
begun
soon
possibl
ideal
within
hour
onset
symptom
thu
suspicion
high
antivir
therapi
administ
without
wait
laboratori
confirm
sever
diseas
treatment
may
still
use
initi
hour
withheld
adamantan
amantadin
rimantidin
block
influenza
protein
ion
channel
thu
prevent
viral
uncoat
howev
widespread
resist
adamantan
longer
recommend
routin
use
neuraminidas
inhibitor
oseltamivir
zanamivir
activ
influenza
b
although
resist
report
oseltamivir
virus
suscept
present
zanamivir
administ
via
inhal
owe
risk
bronchospasm
contraind
person
underli
pulmonari
diseas
latest
inform
treatment
circul
strain
reader
refer
center
diseas
control
prevent
cdc
web
site
http
wwwcdcgovflu
professionalsantivir
patient
influenzalik
ill
ili
clinic
diagnost
effort
focus
detect
viru
rather
antibodi
respons
sampl
collect
ideal
within
hour
onset
ill
initi
antivir
therapi
within
recommend
time
frame
within
hour
maximum
detect
factor
affect
perform
influenza
diagnost
assay
briefli
discuss
box
viral
diagnost
method
evolv
dramat
past
year
summar
tabl
tradit
gold
standard
viral
diagnost
convent
cell
cultur
requir
day
gener
final
result
thu
introduct
rapid
centrifug
cultur
result
day
great
advanc
viral
antigen
assay
immunochromatographi
ic
direct
immunofluoresc
assay
dfa
capabl
yield
result
minut
hour
wide
use
molecular
test
avail
provid
high
sensit
turnaround
time
tat
approxim
hour
thu
advanc
technolog
allow
clinician
redefin
consid
rapid
test
although
ic
assay
frequent
refer
rapid
flu
test
articl
rapid
test
defin
assay
capabl
provid
result
less
hour
time
frame
select
base
recent
releas
nucleic
acid
amplifi
test
naat
theoret
perform
round
clock
core
laboratori
staff
consid
assay
import
establish
perform
characterist
refer
goldstandard
method
convent
cultur
convent
revers
transcriptasepolymeras
chain
reaction
rtpcr
assay
laboratori
provid
collect
guidelin
appropri
test
offer
includ
sampl
type
volum
proper
contain
transport
media
stabil
need
transport
temperatur
special
instruct
especi
commerci
kit
optim
result
samplecollect
instruct
strictli
follow
varieti
sampl
type
studi
influenza
test
box
nasopharyng
np
swab
recommend
recent
consensu
confer
respiratori
viru
test
increas
sensit
may
seen
np
aspir
box
type
specimen
influenza
test
laboratori
valid
assay
specif
specimen
type
deviat
recommend
specimen
may
lead
test
cancel
insert
swab
deep
nasopharynx
past
point
resist
collect
ciliat
respiratori
epitheli
cell
wide
accept
specimen
approv
assay
clear
food
drug
administr
fda
less
expertis
collect
inadequ
specimen
uncommon
swab
type
flock
unflock
transport
media
vari
institut
rapid
diagnosi
influenza
np
wash
rel
invas
requir
expertis
collect
specimen
type
less
wide
use
collect
swab
tissu
usual
place
transport
media
may
vari
test
method
kit
use
factor
associ
specimen
transport
storag
summar
box
laboratori
perform
test
undergon
regulatori
approv
manufactur
guidelin
sampl
type
collect
devic
transport
follow
convent
viral
cultur
tradit
gold
standard
influenza
diagnosi
remain
compar
method
mani
commerci
assay
rapid
cultur
techniqu
wide
appli
respiratori
virus
cultur
techniqu
discuss
box
recent
review
antigendetect
method
amplifi
viru
thu
less
sensit
cultur
naat
addit
assay
perform
influenza
virus
vari
year
year
antigen
variat
circul
strain
immunofluoresc
dfa
cell
affix
glass
slide
stain
antibodi
coupl
fluorophor
examin
fluoresc
microscop
visual
viral
protein
infect
cell
cytospin
prepar
slide
improv
result
respiratori
advantag
detect
virus
cpe
appar
less
expertis
convent
cultur
disadvantag
limit
number
virus
requir
expertis
requir
cell
cultur
facil
microscop
pathogen
may
inadvert
grown
cultur
virus
pool
antibodi
sever
differ
pathogen
use
screen
singl
cell
spot
multipl
virus
includ
respiratori
virus
respiratori
syncyti
viru
rsv
influenza
b
parainfluenza
type
adenoviru
human
metapneumoviru
sampl
screen
posit
addit
test
requir
identifi
infect
virus
compar
later
flow
ic
see
later
discuss
dfa
sensit
allow
assess
sampl
adequaci
ie
suffici
number
target
cell
detect
multipl
virus
singl
test
howev
applic
dfa
limit
technic
requir
eg
fluoresc
microscop
dark
room
technic
expertis
assay
time
one
two
hour
longer
simpler
rapid
test
later
flow
ic
ic
assay
wide
use
detect
influenza
b
separ
assay
avail
rsv
use
influenza
refer
rapid
influenza
diagnost
test
ridt
approv
pointofcar
test
assay
simpl
perform
amen
roundtheclock
test
laboratori
generalist
sampl
minim
manipul
ad
test
kit
read
minut
fig
ridt
reduc
sensit
comparison
techniqu
factor
contribut
reduc
test
perform
outlin
box
semin
articl
onset
influenza
pandem
ginocchio
colleagu
report
realworld
perform
ridt
compar
dfa
rapid
cultur
xtag
rvp
sensit
ridt
influenza
dfa
sensit
rmix
diagnost
hybridsquidel
corp
rapid
cultur
sensit
compar
rvp
sever
factor
could
contribut
reduc
sensit
ridt
dfa
studi
includ
antigen
variat
virus
high
workload
lead
suboptim
perform
interpret
poor
sampl
qualiti
owe
collect
inexperienc
staff
inher
insensit
assay
address
contribut
antigen
variat
analyt
sensit
ridt
cdc
coordin
studi
differ
ridt
avail
unit
state
cdc
prepar
stock
influenza
b
strain
recent
circul
unit
state
high
concentr
dilut
stock
virus
detect
ridt
test
dilut
perform
quickli
fell
less
half
ridt
posit
virus
test
approxim
dilut
virus
detect
ridt
studi
reveal
mark
variabl
ridt
detect
differ
influenza
subtyp
strain
confirm
need
annual
assess
ridt
perform
circul
virus
differ
emphas
cdc
examin
perform
ridt
influenza
emerg
summer
sever
assay
abl
detect
strain
test
ridt
perform
highli
variabl
three
metaanalys
ridt
recent
publish
tabl
among
chartrand
colleagu
look
studi
compar
perform
differ
ridt
either
rtpcr
cultur
gold
standard
specif
pull
sever
differ
factor
includ
studi
perform
comprehens
analysi
ridt
sensit
specif
higher
sensit
seen
studi
children
comparison
adult
p
sensit
lower
studi
use
rtpcr
gold
standard
use
cultur
p
factor
significantli
affect
ridt
sensit
specimen
type
test
point
care
review
studi
durat
patient
symptom
track
highest
sensit
seen
patient
test
day
time
symptom
onset
two
studi
perform
pandem
found
substanti
lower
specif
expect
howev
specif
increas
cours
flu
season
nonlaboratori
staff
perform
interpret
test
gain
expertis
sever
manufactur
develop
system
autom
read
ridt
tabl
sofia
influenza
b
fluoresc
immunoassay
fia
quidel
rapid
detect
flu
b
test
use
antibodi
coupl
fluoresc
compound
wherea
bd
veritor
system
use
proprietari
enhanc
colloidalgold
particl
detect
devic
standard
interpret
among
personnel
bd
veritor
walkaway
function
read
time
could
still
vari
sever
independ
studi
sofia
veritor
rapid
detect
system
publish
taken
togeth
studi
confirm
high
degre
certainti
previous
report
name
clinic
analyt
sensit
ridt
less
method
includ
dfa
cultur
rtpcr
studi
address
clinic
util
costeffect
ridt
low
sensit
ridt
impetu
develop
molecular
assay
provid
high
sensit
rel
rapid
tat
molecular
method
viru
detect
gain
favor
sensit
equal
exce
cultur
quantit
detect
virus
otherwis
uncultur
tat
day
less
multiplex
method
allow
detect
multipl
analyt
singl
test
extract
render
viru
noninfecti
naat
histor
restrict
larger
academ
center
refer
laboratori
recent
develop
kit
approv
food
drug
administr
fda
less
complex
assay
allow
highli
sensit
method
becom
wide
use
convent
pcr
consist
step
extract
purif
nucleic
acid
amplif
target
sequenc
use
specif
primer
dna
polymeras
detect
amplifi
fragment
box
fig
step
must
perform
separ
space
unidirect
workflow
limit
crosscontamin
falseposit
result
rna
virus
influenza
virus
viral
rna
must
first
revers
transcrib
cdna
pcr
amplif
ie
rtpcr
assay
amplifi
product
analyz
independ
amplif
step
endpoint
pcr
assay
wherea
wherebi
amplif
detect
occur
simultan
said
realtim
pcr
assay
advantag
disadvantag
assay
format
list
tabl
laboratori
gener
move
endpoint
realtim
pcr
assay
sever
highli
multiplex
commerci
kit
detect
respiratori
virus
use
endpoint
method
realtim
pcr
method
major
impact
diagnost
test
combin
amplif
detect
one
step
see
fig
combin
shorten
assay
time
reduc
amplicon
crosscontamin
reaction
tube
open
allow
visual
amplif
result
unfold
real
time
step
perform
one
room
realtim
pcr
method
use
nonsequ
specif
fluoresc
dna
bind
dye
sybr
green
sequencespecif
fluoresc
dna
probe
thu
realtim
assay
requir
use
thermocycl
builtin
light
sourc
filter
detector
assay
use
sybr
dye
gain
specif
meltcurv
analysi
wherein
fluoresc
monitor
increas
temperatur
complet
certain
number
cycl
melt
doublestrand
dna
occur
sequencespecif
manner
associ
chang
detect
fluoresc
one
common
realtim
pcr
assay
use
hydrolysi
probe
eg
taqman
probe
contain
report
fluorophor
quencher
close
proxim
probe
intact
fluoresc
report
quench
probe
bind
dna
segment
undergo
amplif
nucleas
activ
taq
polymeras
degrad
probe
releas
report
quencher
lead
detect
fluoresc
assay
use
design
specif
determin
primer
probe
sequenc
although
product
may
amplifi
mismatch
probe
might
lead
fail
hydrolysi
detect
fluoresc
realtim
assay
design
circumv
problem
incorpor
fluoresc
report
quencher
primer
sever
differ
thermocycl
commerci
avail
devic
differ
mechan
temperatur
cycl
occur
eg
metal
block
heat
air
reaction
vessel
eg
plate
capillari
tube
proprietari
cartridg
fluoresc
channel
avail
among
paramet
factor
determin
quickli
reaction
take
place
number
analyt
may
detect
compat
commerci
assay
multiplex
refer
detect
analyt
sampl
singl
test
reaction
realtim
pcr
instrument
contain
sever
differ
filter
andor
light
sourc
allow
detect
differ
fluorophor
given
need
intern
control
refer
dye
instrument
limit
sever
differ
assay
commerci
avail
capabl
detect
influenza
influenza
b
rsv
well
intern
control
sever
manufactur
develop
novel
method
multiplex
differ
target
respiratori
pathogen
biofir
luminex
genmark
fdaclear
highli
multiplex
assay
compani
includ
seegen
qiagen
nanospher
highli
multiplex
respiratori
pathogen
panel
may
avail
vitro
diagnost
ivd
researchus
ruo
test
depend
laboratori
locat
biofir
filmarray
nanospher
verigen
discuss
herein
recent
review
clinic
laboratori
medicin
discuss
luminex
genmark
system
tat
current
molecular
assay
vari
minut
hour
start
finish
mani
realtim
pcr
assay
go
sampl
result
approxim
hour
howev
like
reflect
true
clinic
tat
assay
workflow
compat
random
accessondemand
process
test
extract
amplificationdetect
instrument
often
design
use
singl
specimen
laboratori
protocol
often
requir
sever
control
assay
run
lead
rapidli
escal
reagent
cost
singl
sampl
rapid
diagnosi
influenza
run
laboratori
perform
naat
influenza
virus
batch
frequenc
run
determin
staf
workload
clinic
need
strategi
delay
clinic
tat
beyond
actual
time
requir
perform
assay
past
year
naat
design
randomaccess
capabl
give
result
less
hour
clear
fda
detect
influenza
b
tabl
assay
use
sever
uniqu
modif
tradit
extractionamplificationdetect
workflow
requir
convent
naat
see
fig
test
system
amen
implement
laboratorydevelop
test
ldt
proprietari
dispos
howev
classifi
moder
complex
allow
perform
much
broader
spectrum
laboratori
personnel
handson
requir
minim
regard
time
manipul
focu
diagnost
releas
fdaclear
highli
complex
multiplex
realtim
rtpcr
assay
detect
influenza
influenza
b
rsv
requir
separ
extract
step
focu
subsequ
receiv
fda
clearanc
flu
ab
rsv
direct
extract
assay
use
larger
sampl
input
volum
possibl
previou
assay
focu
sever
fdaclear
assay
avail
platform
sever
analytespecif
reagent
assay
avail
bacteri
viral
target
platform
amen
implement
ldt
includ
fulli
homebrew
assay
adapt
exist
assay
new
platform
may
straightforward
genexpert
flu
assay
compon
found
selfcontain
cartridg
seri
chamber
hous
appropri
reagent
use
differ
assay
function
sever
assay
avail
use
genexpert
system
includ
viral
bacteri
test
filmarray
use
seri
differ
chamber
mylar
pouch
separ
extract
firststag
amplif
secondstag
amplificationrealtim
detect
respiratori
pathogen
use
nest
pcr
approach
wherebi
product
firststag
pcr
reaction
amplifi
target
sever
pathogen
dilut
pathogenspecif
secondstag
pcr
array
secondstag
pcr
amplif
detect
real
time
targetindepend
dnabind
dye
amplif
specif
confirm
meltcurv
analysi
throughput
limit
specimen
per
instrument
highli
multiplex
assay
detect
bacteri
fungal
pathogen
blood
cultur
recent
fdaclear
biofir
instrument
verigen
system
use
gold
nanoparticl
novel
mean
detect
amplifi
nucleic
acid
sampl
undergo
extract
rtpcr
incub
slideimmobil
gold
nanoparticl
singleus
cartridg
verigen
processor
slide
remov
processor
presenc
analyt
detect
reader
processor
occupi
continu
specimen
potenti
limit
throughput
highli
multiplex
respiratori
viru
assay
addit
respiratori
pathogen
current
ruo
test
verigen
clinic
diagnost
assay
microbiolog
human
geneticspharmacogenet
applic
fdaclear
platform
like
genexpert
iquum
liat
influenza
ab
assay
perform
selfcontain
test
cartridg
influenza
ab
assay
test
current
avail
platform
like
filmarray
verigen
liat
analyz
handl
test
time
potenti
limit
throughput
newli
develop
assay
avail
short
time
comparison
studi
limit
subject
fda
review
publicli
avail
result
fdaclear
document
product
insert
suggest
sensit
specif
consist
mani
naat
howev
regulatori
approv
genexpert
flu
compar
naat
other
compar
cultur
naat
gener
sensit
cultur
thu
would
lead
overestim
sensit
assay
final
data
fda
trial
like
obtain
ideal
circumst
may
repres
realworld
perform
thu
sensit
specif
determin
fda
trial
may
born
subsequ
postmarket
studi
use
naat
gold
standard
see
later
discuss
perform
filmarray
thoroughli
assess
least
differ
comparison
studi
publish
among
van
wesenbeeck
colleagu
compar
assay
tat
less
hour
filmarray
verigen
five
studi
compar
filmarray
highli
multiplex
assay
includ
luminex
rvp
rvp
fast
qiagen
resplex
ii
genmark
esensor
other
use
ldt
prodess
compar
method
studi
differenti
among
influenza
subtyp
sensit
influenza
assay
rang
specif
studi
detect
influenza
b
sensit
specif
across
studi
perform
filmarray
influenza
subtyp
variabl
nearli
report
also
compar
perform
analyt
contain
filmarray
panel
either
comparison
highli
multiplex
test
commerci
assay
ldt
xpert
flu
assay
examin
sever
studi
comparison
xtag
rvp
sever
differ
ldt
andor
cultur
studi
found
sensit
specif
influenza
sensit
specif
influenza
b
howev
origin
xpert
flu
assay
releas
reformul
version
assay
addit
primer
pair
influenza
releas
late
publish
studi
specifi
version
assay
use
three
studi
examin
perform
verigen
comparison
naat
includ
extract
focu
flu
ab
rsv
among
other
sensit
studi
exceed
specif
influenza
third
studi
found
sensit
high
invalid
rate
perform
influenza
b
assess
one
studi
sensit
specif
studi
examin
perform
iquum
liat
publish
one
studi
focu
flu
ab
rsv
direct
kit
publish
woodberri
colleagu
found
posit
agreement
influenza
influenza
b
investig
suspect
thermocycl
malfunct
could
neg
affect
assay
perform
especi
influenza
b
two
studi
compar
perform
focu
flu
ab
rsv
kit
without
extract
found
much
higher
sensit
specif
influenza
b
howev
albi
colleagu
use
fdaclear
extract
protocol
assay
found
sensit
influenza
b
respect
studi
vari
qualiti
sampl
size
mixtur
prospect
retrospect
design
perform
year
limit
circul
strain
nonetheless
demonstr
potenti
realworld
perform
assay
except
studi
fail
address
import
question
perform
compar
among
influenza
naat
rapid
tat
headtohead
comparison
rapid
naat
perform
studi
need
help
laboratori
make
inform
decis
assay
select
current
avail
naat
capabl
deliv
highord
multiplex
tat
less
hour
high
throughput
reagent
instrument
cost
also
substanti
mani
assay
furthermor
influenza
test
volum
fairli
season
instrument
dedic
influenza
test
like
sit
idl
mani
month
year
test
platform
discuss
limit
test
menu
may
assay
suffici
volum
perform
yearround
convers
instrument
appropri
demand
throughout
year
may
unabl
handl
increas
volum
associ
influenza
season
genexpert
focu
diagnost
liat
assay
reli
realtim
pcr
degre
multiplex
avail
platform
intrins
limit
abil
instrument
detect
multipl
fluorophor
chang
virus
detect
possibl
eg
rsv
instead
influenza
would
requir
new
regulatori
approv
contrast
verigen
filmarray
system
capabl
highord
multiplex
simultan
detect
respiratori
pathogen
andor
pathogen
subtyp
throughput
limit
instrument
select
assay
essenti
identifi
test
perform
whether
multiplex
test
may
appropri
tabl
sever
studi
perform
assess
clinic
impact
rapid
influenza
test
sever
random
studi
compar
triagebas
protocol
test
ie
test
result
avail
patient
seen
standard
care
although
result
trial
mix
suggest
avail
rapid
influenza
test
decreas
diagnost
evalu
antibiot
util
length
cost
visit
emerg
room
result
pronounc
individu
test
posit
influenza
studi
perform
analysi
trial
necessarili
power
make
comparison
studi
look
pediatr
patient
emerg
roomurg
care
set
recent
metaanalysi
studi
recent
conclud
ridt
use
reduc
diagnost
test
larger
adequ
power
studi
need
fulli
address
issu
sever
nonrandom
studi
includ
adult
inpati
use
chart
review
compar
individu
test
posit
influenza
test
neg
studi
found
decreas
antibiot
usag
reduc
length
visitlength
stay
among
individu
test
influenza
posit
one
studi
among
hospit
adult
cardiopulmonari
diseas
posit
ridt
led
reduc
antibiot
use
increas
antivir
therapi
howev
sever
influenzaposit
adult
continu
receiv
antibiot
lead
investig
conclud
better
tool
need
exclud
bacteri
infect
reduc
antibiot
util
studi
assess
whether
rapid
influenza
test
avail
result
affect
prescript
antivir
like
due
number
studi
examin
children
two
studi
show
antivir
prescript
appropri
increas
among
patient
test
posit
influenza
studi
examin
impact
rapid
influenza
test
bedmanag
decis
beyond
admiss
hospit
discharg
emerg
depart
systemat
manner
previous
cite
studi
use
either
ridt
dfa
rapid
test
studi
molecular
test
limit
oosterheert
colleagu
examin
contribut
pcr
panel
viral
atyp
bacteri
pathogen
hospit
adult
although
pcr
increas
diagnost
yield
cost
care
differ
antibiot
util
patient
avail
pcr
result
clinic
impact
biofir
filmarray
report
one
studi
found
decreas
tat
compar
previou
year
time
prescript
oseltamivir
mani
argument
put
forth
ration
rapid
influenza
test
also
hold
true
highli
multiplex
assay
studi
depth
test
specif
adenoviru
dfa
affect
differenti
diagnosi
diagnost
evalu
manag
hospit
children
byington
colleagu
found
result
rsv
test
dfa
also
affect
patient
care
wellcharacter
respiratori
pathogen
identif
potenti
caus
agent
could
benefici
sensit
multiplex
assay
lead
higher
rate
identif
coinfect
infect
agent
associ
common
cold
rhinoviru
human
coronavirus
former
case
difficult
determin
viru
respons
patient
current
present
rhinovirus
coronavirus
caus
sever
diseas
especi
immunocompromis
host
yet
may
disregard
normal
flora
provid
altern
symptom
may
ascrib
virus
process
may
contribut
diseas
possibl
identifi
infect
influenza
respiratori
virus
high
sensit
littl
hour
manufactur
also
develop
advanc
pointofcar
ic
assay
seek
minim
known
limit
mani
ridt
thu
laboratori
institut
wide
varieti
assay
platform
choos
implement
rapid
influenza
test
best
way
clinic
implement
assay
remain
unclear
mani
differ
factor
must
consid
choos
optim
test
algorithm
use
interpret
impact
rapid
respiratori
viru
assay
vari
among
children
adult
outpati
inpati
immunosuppress
forth
patient
popul
serv
among
import
consider
decid
whether
test
clinician
guidanc
educ
need
optim
intervent
occur
help
guid
laboratori
provid
decis
make
studi
urgent
need
determin
clinic
util
impact
outcom
costeffect
rapid
antigen
naat
influenza
respiratori
virus
differ
patient
group
clinic
set
